Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, shared early observations from its ongoing Phase I/IIa first-in-human trial of CMND-100, a non-hallucinogenic compound being studied as a treatment for alcohol use disorder (AUD).

The update, drawn from a June 10 webinar titled "Inside MEAI," featured remarks from two principal investigators: Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University. Both described a generally positive early impression of CMND-100 based on their experience in the trial to date.

Key observations shared by the investigators included a promising early safety profile, with no meaningful adverse effects or cardiac safety concerns reported so far. Recruitment has progressed despite strict eligibility criteria for healthy volunteers. The investigators noted that the compound's non-hallucinogenic profile could allow for a simpler treatment model that may not require hospitalization, intensive monitoring, or mandatory psychiatric supervision, though no conclusions about efficacy have been drawn at this stage.

The investigators also noted that the absence of hallucinogenic effects improves blinding in the study and allows for a clearer assessment of the compound's direct pharmacological effects.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: "We are very pleased that our joint work to date has been smooth and productive."

The webinar also covered study design, dose escalation, pharmacokinetics, and participant experience. The press release noted that further research would be required to explore potential applications of the compound beyond AUD.

Clearmind holds a portfolio of 19 patent families, including 32 granted patents. The company's shares trade on the Nasdaq exchange under the ticker CMND.